Cord blood transplantation (CBT) in hemoglobinopathies. Eurocord

R Miniero; V Rocha; P Saracco; F Locatelli; B Brichard; A Nagler; I Roberts; I Yaniv; M Beksac; F Bernaudin; E Gluckman

Cord blood transplantation (CBT) in hemoglobinopathies. Eurocord

Bone Marrow Transplant. 1998 Jul:22 Suppl 1:S78-9.

Authors

R Miniero¹, V Rocha, P Saracco, F Locatelli, B Brichard, A Nagler, I Roberts, I Yaniv, M Beksac, F Bernaudin, E Gluckman

Affiliation

¹ Eurocord Transplant Registry, Unité de Recherche, Hôpital Saint-Louis, Paris, France.

PMID: 9715898

Abstract

Patients with beta-thalassemia (Hbeta th) and sickle cell anemia (SCA) can be treated with bone marrow transplantation. Stem cells from cord blood have several theoretical advantages, however, the place of cord blood transplant for hemoglobinopathies has not yet been established. We report here the EUROCORD experience of 10 patients (Hbeta th = 7, SCA = 3) transplanted with related cord blood.

Publication types

Clinical Trial

MeSH terms

Anemia, Sickle Cell / therapy*
Antineoplastic Agents, Alkylating / therapeutic use
Child
Child, Preschool
Cyclosporine / therapeutic use
Female
Fetal Blood*
Graft vs Host Disease / prevention & control
Hematopoietic Stem Cell Transplantation*
Humans
Immunosuppressive Agents / therapeutic use
Infant
Male
Methotrexate / therapeutic use
Prospective Studies
Thiotepa / therapeutic use
Treatment Outcome
beta-Thalassemia / therapy*

Substances

Antineoplastic Agents, Alkylating
Immunosuppressive Agents
Cyclosporine
Thiotepa
Methotrexate